antiviral(efficacy(and(host(immune(response(induction(with...
TRANSCRIPT
ANTIVIRAL EFFICACY AND HOST IMMUNE RESPONSE INDUCTION WITH SB 9200, AN ORAL PRODRUG OF THE DINUCLEOTIDE SB 9000, IN COMBINATION WITH ENTECAVIR IN THE WOODCHUCK MODEL OF CHRONIC HEPATITIS B Kyle Korolowicz1, Maria Balarezo1, Radhakrishnan Iyer2, Seetharamaiyer Padmanabhan2, Dillon Cleary2, Rayomand Gimi2, Anjaneyulu Sheri2, Manasa Suresh1, Changsuek Yon1, Robin Tucker3, Nezam Afdhal2, and Stephan Menne1 1Microbiology and Immunology, Georgetown University Medical Center, Washington, DC, 2Spring Bank PharmaceuNcals, Milford, MA, 3Department of ComparaNve Medicine, Georgetown University Medical Center, Washington, DC, United States pany
BACKGROUND
SB 9200 is a small orally bioavailable dinucleoNde that acNvates the cellular viral sensors RIG-‐I and NOD2 causing the inducNon of IFN signaling cascade for anNviral defense (1, 2). In preclinical studies, SB 9200 has shown to be a potent agent against hepaNNs B virus (HBV) (1, 3). In woodchucks chronically infected with woodchuck hepaNNs virus (WHV), SB 9200 monotherapy for 12 weeks at two select doses resulted in potent anNviral acNvity (4).
OBJECTIVES
The aim of this study was to evaluate the overall anNviral response in woodchucks upon inducNon of innate immune response first by treatment with SB 9200 followed by Entecavir (ETV) treatment versus reducNon of viral burden with ETV treatment followed by immune modulaNon with SB 9200.
SUMMARY At the end of treatment in Group 2, average reducNons of 6.4 log10 in serum WHV DNA and 3.3 log10 in WHsAg were observed whereas in Group 1, average reducNons of 4.2 log10 and 1.1 log 10 in serum WHV DNA and WHsAg were seen compared to pretreatment levels. Treatment demonstrated significant reducNons of WHV DNA RI, cccDNA, and RNA in Group 2 (76%, 49%, and 51%) and Group 1 (57%, 39%, and 41%). Following cessaNon of treatment and the 8-‐week follow-‐up period, recrudescence of WHV replicaNon was observed in Group 1, whereas recrudescence in Group 2 was much delayed with viremia and anNgenemia staying at 1.7 and 0.7 log10 below pretreatment levels. Overall, both treatment regimens slightly reduced hepaNc WHV anNgen expression and slowed liver disease progression. Seroconversion to anN-‐WHs anNbody was not observed. The anNviral effects were also associated with the inducNon of IFN-‐α, IFN-‐β, OAS-‐1, CXCL10, ISG15, and IL-‐6 in blood and liver, which were more pronounced in Group 2 compared to Group 1.
RESULTS
CONCLUSIONS REFERENCES
MATERIALS & METHODS
Two groups of five woodchucks were treated orally with SB 9200 (30 mg/kg/day) and ETV (0.5 mg/kg/day). Group 1 received ETV for 4 weeks followed by SB 9200 for 12 weeks. Group 2 received SB 9200 for 12 weeks followed by ETV for 4 weeks. Both groups were monitored for 8 weeks post-‐treatment. Endpoints included PD, tolerability and anNviral efficacy.
Safety parameters included hematology, clinical chemistry, body weights, body temperatures and daily observaNons.
Serum DNA load was determined by slot blot hybridizaNon and samples below the limit of detecNon were further evaluated by PCR. Serum surface anNgen (WHsAg) level and anNbod Nter against WHsAg (anN-‐WHs) were assayed by ELISA. HepaNc levels of WHV RNA, covalently-‐closed circular (ccc) DNA, and DNA replicaNve intermediates (RI) were measured quanNtaNvely by Northern or Southern blot hybridizaNon, respecNvely. InducNon of innate immune response to SB 9200 treatment was tested by measuring RNA levels of IFN-‐α, IFN-‐β, IL-‐6, CXCL10, OAS1 and ISG15 in whole blood and liver.
InducNon of host innate immune response by pretreatment with SB 9200 followed by ETV in woodchucks resulted in significant declines in viral DNA, RNA, and anNgens that was superior to that seen using the strategy of viral reducNon with ETV followed by immune modulaNon. These data support the planned Phase II clinical trial of SB 9200 alone and in combinaNon with a nucleoside in the treatment of chronic HBV.
1. Coughlin JE, et al., Bioorg Med Chem Lek 2010;20:1783-‐1786 2. Cunningham ME, et al., Hepatology 2013;58:92A-‐207A, Abstract 473 3. Iyer RP, et al., AnNmicrob Agents Chemother 2004;48:2318-‐2320 4. Korolowicz K, et al., J Hepatol 2015; 62:S557
Tips for InserHng Graphs
or Images Note: Skip the following procedure if your graphs were created in PowerPoint®, Illustrator (eps file) or Excel.
Image checking procedure: Aoer you insert the image (72 dpi screen resoluNon) and resize* to fit, right click on it and select Format Picture. When the pop-‐up window comes up, click on size and check the scale. The image will print beker if its width and height scale is at 25% or lower (20% or 10%, etc.)
If the scale of the image is higher than 25%, try to replace it with a larger size (more dpi, e.g. 300dpi) image if possible. (Note: This should not be done by manually stretching the image to a larger size.)
If the resoluNon of the image is 300 dpi or higher (400 or 600 dpi), then check to make sure its scale is not higher than 100%.
*To resize an image – Click on the image, hold the Shio key down and drag the bokom right corner to resize the image in proporNon.
(Delete this box when inserNng your text or image. This is only a reminder.)
Tips for Title/Headers Bar Color
How to change the background color for the poster Htle and headers:
Right click on the bar and select Format Autoshape. When the pop-‐up window comes up, select your color under “Fill” and then “Color” menu. For more effects select Fill Effects under the Color opNon.
(Delete this box when inserNng your text or image. This is only a reminder.)
Tips for Excel Charts Copy and paste your Excel chart. The chart can be stretched to fit as required. If you need to edits parts of the chart, we recommend you edit the original chart in Excel, then re-‐paste the new chart.
(Delete this box when inserNng your text or image. This is only a reminder.)
Contact InformaHon Stephan Menne: [email protected]; Radhakrishnan P. Iyer: [email protected]
PRINT TO 200% TO FIT PAPER BOARDS (190x90cm)
REFERENCES This study was supported by IDIQ contract HHSN272201000011I, task order HHSN27200002 (D06) to Georgetown University Medical Center and by R01 grant AI094469 to Spring Bank PharmaceuNcals, Inc. from NIAID/DMID.
Fig. 1. Changes in levels of serum WHV DNA (top panels) and WHsAg (bo\om panels) relaNve to T0 (pretreatment baseline) in individual woodchucks administered ETV + SB 9200 (a, d) or SB 9200 + ETV (b, e),
and mean of each group (c, f).
Fig. 2. Changes in mean hepaNc levels of WHV RI DNA (a), WHV cccDNA (b), and WHV RNA (c) relaNve to week -‐1 (pretreatment baseline) in response to treatment with ETV + SB 9200 or SB 9200 + ETV.
SequenHal treatment with SB 9200 followed by ETV results in marked suppression of serum viremia and anHgenemia and in delayed recrudescence of viral replicaHon compared to
sequenHal treatment with ETV followed by SB 9200
SequenHal treatment with SB 9200 followed by ETV induces more pronounced reducHon in hepaHc levels of WHV nucleic acids than sequenHal treatment with ETV followed by SB 9200
SequenHal treatment with SB 9200 followed by ETV induces pronounced and someHmes long-‐lasHng expression increases of type I IFNs, cytokine and ISGs in blood
Fig. 5. Changes in mean blood transcript levels of IFN-‐α, IFN-‐β, and IL-‐6 (top panels) and of CXCL10, OAS1 and ISG15 (bo\om panels) in response to treatment with ETV + SB 9200 (a, c) or SB 9200 + ETV (b, d).
Delayed recrudescence of viral replicaHon following sequenHal treatment with SB 9200 and ETV is associated with expression increases of type I IFNs, cytokine and ISGs in liver
Fig. 6. Changes in mean liver transcript levels of IFN-‐α, IFN-‐β, and IL-‐6 (top panels) and of CXCL10, OAS1 and ISG15 (bo\om panels) in response to treatment with ETV + SB 9200 (a, c) or SB 9200 + ETV (b, d).
Fig. 3. Changes in cytoplasmic WHcAg (top panels) and membranous WHsAg expression (bo\om panels) in response to treatment with ETV + SB 9200 (a, c) or SB 9200 + ETV (b, d). Changes in mean serum WHV DNA relaNve to T0 (pretreatment baseline) is ploked on the leo y-‐axis. The mean immunohistochemistry (IHC) scores for anNgen expression in liver are ploked on the right y-‐axis.
SequenHal treatment with SB 9200 followed by ETV results in greater reducHon of hepaHc WHV anHgen expression than sequenHal treatment with ETV and SB 9200
SequenHal treatment with SB 9200 and ETV or ETV and SB 9200 reduces liver steatosis
Fig. 4. Changes in liver steatosis in response to treatment with ETV + SB 9200 (a) or SB 9200 + ETV (b). Changes in mean serum WHV DNA relaNve to T0 (pretreatment baseline) is ploked on the leo y-‐axis. The mean score for hepaNc steatosis is ploked on the right y-‐axis.